Digital Medicine System Provides Clinicians with an Accurate Tool to Manage Adherence
etectRx™, a privately-held digital health company, is pleased to announced the successful completion of a clinical study using the ID-Cap™ System to track and report medication adherence in HIV prevention. The researchers utilized etectRx’s ID-Cap System to examine medication adherence patterns in 16 study participants over three months for the HIV prevention drug TRUVADA for PrEP® (Pre-Exposure Prophylaxis). When used properly, the technology successfully recorded medication ingestions on 98% of occasions.
The study was conducted at The Fenway Institute at Fenway Health, one of the leading HIV research organizations in the world. Gilead Sciences, a global pharmaceutical leader with a portfolio of products for HIV treatment and prevention, funded the study. The study was led by principal investigator, Dr. Peter Chai, M.D., M.M.S., toxicologist in the Department of Emergency Medicine at Brigham and Women’s Hospital and Assistant Professor at Harvard Medical School.
Doses were self-administered and the devices were used by study participants in their homes or other locations to allow remote monitoring of ingestion events in real-time. Use of the ID-Cap System enhanced understanding of how adherence can be increased among populations at risk for HIV infection.
“Improved medication adherence is an essential pillar to addressing the UNAIDS 90-90-90 goals to end the AIDS epidemic. We look forward to sharing the results of this study that demonstrate the value of measuring adherence using solutions, such as the ID-Cap System, that are acceptable to patients, useful to clinicians, and feasible to implement in practice,” said Dr. Peter Chai, the principal investigator of the study. “We are excited to continue our collaboration with etectRx to demonstrate the potential of digital pills to improve medication adherence and to assess the impact of this technology on the health and lives of people at risk of contracting HIV and those living with HIV.”
Preliminary study results will be presented by Dr. Chai at the upcoming IAPAC Adherence 2020 meeting (15th International Conference on HIV Treatment and Prevention Adherence) in Orlando in November.
